Want to see JAZZ full AI Analyst Report?
JAZZ Stock Chart & Stats
$203.42
-$1.17(-0.95%)
At close: 4:00 PM EST
$203.42
-$1.17(-0.95%)
Day’s Range― - ―
52-Week Range$105.00 - $250.49
Previous CloseN/A
Volume75.28K
Average Volume (3M)805.41K
Market Cap
$15.55B
Enterprise Value$15.04K
Total Cash (Recent Filing)$2.87B
Total Debt (Recent Filing)$5.42B
Price to Earnings (P/E)593.8
Beta0.71
Next Earnings
Aug 03, 2026EPS Estimate
6.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding62,817,627
10 Day Avg. Volume724,859
30 Day Avg. Volume805,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio9.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$264.50Price Target Upside30.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)25.29
Revenue Forecast (FY)$4.51B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And LiquidityConsistent, large operating cash flows and a $2.9B cash/investment balance provide durable financial flexibility. This supports ongoing R&D, commercial investment, or targeted M&A without immediate reliance on capital markets, cushioning the business through multi-quarter variability.
Exceptionally High Gross MarginsSustained mid‑80s gross margins indicate structural pricing power and low incremental cost to sell, enabling strong cash conversion even if revenue growth moderates. High gross margins underpin long‑term ability to fund pipeline work and absorb commercial reinvestment or pricing pressure.
Diversified Growth From Oncology And Pipeline CatalystsA rapidly growing oncology franchise plus near‑term regulatory catalysts (zanidatumab PDUFA) and early traction for recent launches (Midevo) create multiple structural revenue drivers. Diversification away from a single franchise reduces long‑run concentration risk and supports sustained growth.
Bears Say
Substantial Absolute Debt LoadA multi‑billion dollar debt stock, while leverage metrics have improved, constrains long‑term strategic optionality. Interest and principal obligations can limit capital allocation to dividends, buybacks, or acquisitive growth, especially if earnings remain uneven across reporting periods.
Volatile Earnings And Earnings QualityWide swings in reported profitability undermine earnings reliability and make multi‑period forecasting harder for investors and lenders. This variability can increase perceived risk, raise financing costs, and complicate long‑term planning for R&D, launches, and portfolio investment.
Structural Competition In Core Sleep FranchiseAnticipated generic oxybate volume growth and new wake‑promoter entrants represent a durable threat to Xywav/Xyrem revenues and mix. Loss of share or pricing pressure in a core chronic franchise could materially reduce cash flow and margin sustainability over multiple quarters.
Jazz Pharmaceuticals News
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $105.00 and its highest was $250.49 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $15.55B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 13 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 05, 2026. The company reported $6.34 earnings per share for the quarter, beating the consensus estimate of $4.641 by $1.699.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 6.18.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 62,817,627 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.34 in its last earnings report, beating expectations of $4.641. Following the earnings report the stock price went up 7.684%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$264.50 (30.03% Upside)
$264.50 (30.03% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 150.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.82%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ Stock 12 Month Forecast
Average Price Target
$264.50
▲(30.03% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Bio-Techne
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
3.53% Insiders
30.45% Mutual Funds
0.75% Other Institutional Investors
40.58% Public Companies and
Individual Investors